ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.60828
-0.08%
Brent Oil
81.56
-1.07%
Bitcoin
69,802.21
-0.47%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Anebulo Pharmaceuticals Inc (ANEB)

  7. Anebulo Pharmaceuticals Inc (ANEB) Noticias

ANEB

Anebulo Pharmaceuticals (ANEB)

Anebulo Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ANEB
FechaHoraFuenteTítuloSímboloCompañía
15/05/202415:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANEBAnebulo Pharmaceuticals Inc
15/05/202412:05Business WireAnebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
13/02/202415:05Business WireAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202315:05Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202308:31Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/10/202308:22Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
19/10/202316:18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202315:06Business WireAnebulo Pharmaceuticals Announces New CEONASDAQ:ANEBAnebulo Pharmaceuticals Inc
06/10/202315:06Business WireAnebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/10/202316:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
22/09/202315:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANEBAnebulo Pharmaceuticals Inc
20/09/202315:29Business WireAnebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
30/08/202307:00Business WireAnebulo Pharmaceuticals to Present at Upcoming Investor and Scientific ConferencesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
21/08/202307:00Business WireAnebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 ExtensionNASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202315:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202307:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/05/202307:00PR Newswire (US)Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
04/04/202317:33Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
28/03/202307:00PR Newswire (US)Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
08/03/202307:00PR Newswire (US)Anebulo Pharmaceuticals Expands its Integrated and Outsourced SolutionsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/02/202307:38Business Wire Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
09/01/202307:00Business WireAnebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid IntoxicationNASDAQ:ANEBAnebulo Pharmaceuticals Inc
14/11/202205:13Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
10/11/202207:00Business WireAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent UpdatesNASDAQ:ANEBAnebulo Pharmaceuticals Inc
02/11/202215:07Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
01/11/202215:00Business WireAnebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of DirectorsNASDAQ:ANEBAnebulo Pharmaceuticals Inc
17/10/202208:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
11/10/202205:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
03/10/202218:54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ANEBAnebulo Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ANEB

Su Consulta Reciente

EU
IUCAP
Ossiam UCAP iNav
TSX
IIAE.F
Invesco S&P Intl Develop...
GATE
UBXSUSDT
UBXS Token
BOV
AIGB34R
American
NYSE
XTRE
BondBloxx ETF Tr
COIN
LUSDUST
LUSD Stablecoin
USOTC
PBHDF
Paramount Bed (PK)
BIT
S28672
Societe Generale Effekten
NASDAQ
SQFT
Presidio Property
BIT
UC8XWC
Unicredit Bank
TSX
WELL
WELL Health Technologies
COIN
XGMGBP
BIT
XSX6
XtrackersStoxx Europe 60...
EU
G218T
G218T
ASX
CYPN
USOTC
PHOT
Growlife (CE)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados